Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Guardant Health Inc (NASDAQ: GH) closed at $100.0 in the last session, down -2.60% from day before closing price of $102.67. In other words, the price has decreased by -$2.60 from its previous closing price. On the day, 3.26 million shares were traded. GH stock price reached its highest trading level at $103.0 during the session, while it also had its lowest trading level at $97.44.
Ratios:
We take a closer look at GH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.12 and its Current Ratio is at 3.50.
On September 25, 2025, Wolfe Research Upgraded its rating to Outperform which previously was Peer Perform but kept the price unchanged to $75.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Eltoukhy Helmy bought 90,565 shares for $103.82 per share.
Talasaz AmirAli sold 100,000 shares of GH for $10,505,474 on Dec 08 ’25. The Co-Chief Executive Officer now owns 168,223 shares after completing the transaction at $105.05 per share. On Dec 08 ’25, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 2,000 shares for $104.60 each. As a result, the insider received 209,204 and left with 22,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 12987442176 and an Enterprise Value of 13350471680. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.33. Its current Enterprise Value per Revenue stands at 14.792 whereas that against EBITDA is -33.194.
Stock Price History:
The Beta on a monthly basis for GH is 1.59, which has changed by 2.172744 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $112.43, while it has fallen to a 52-week low of $29.91. The 50-Day Moving Average of the stock is 11.92%, while the 200-Day Moving Average is calculated to be 69.05%.
Shares Statistics:
According to the various share statistics, GH traded on average about 2.61M shares per day over the past 3-months and 1888730 shares per day over the past 10 days. A total of 125.01M shares are outstanding, with a floating share count of 124.47M. Insiders hold about 3.79% of the company’s shares, while institutions hold 96.59% stake in the company. Shares short for GH as of 1764288000 were 9245963 with a Short Ratio of 3.54, compared to 1761868800 on 8415877. Therefore, it implies a Short% of Shares Outstanding of 9245963 and a Short% of Float of 7.46.
Earnings Estimates
A comprehensive evaluation of Guardant Health Inc (GH) is underway, with the input of 15.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.26 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.67 and -$2.2 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$1.44, with 17.0 analysts recommending between -$0.91 and -$2.31.
Revenue Estimates
According to 19 analysts,. The current quarter’s revenue is expected to be $267.76M. It ranges from a high estimate of $270M to a low estimate of $264.6M. As of. The current estimate, Guardant Health Inc’s year-ago sales were $201.81MFor the next quarter, 19 analysts are estimating revenue of $271.36M. There is a high estimate of $284.1M for the next quarter, whereas the lowest estimate is $255.92M.
A total of 23 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $970.8M, while the lowest revenue estimate was $965.3M, resulting in an average revenue estimate of $968.56M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.32B and the low estimate is $1.16B.
